A detailed history of Northern Trust Corp transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 945,171 shares of MRSN stock, worth $1.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
945,171
Previous 931,406 1.48%
Holding current value
$1.9 Million
Previous $2.16 Million 96.02%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$2.16 - $5.94 $29,732 - $81,764
13,765 Added 1.48%
945,171 $4.23 Million
Q4 2023

Feb 13, 2024

SELL
$1.11 - $2.34 $110,089 - $232,081
-99,180 Reduced 9.62%
931,406 $2.16 Million
Q3 2023

Nov 13, 2023

SELL
$1.06 - $3.91 $72,625 - $267,893
-68,515 Reduced 6.23%
1,030,586 $1.31 Million
Q2 2023

Aug 11, 2023

BUY
$3.08 - $9.55 $660,561 - $2.05 Million
214,468 Added 24.24%
1,099,101 $3.62 Million
Q1 2023

May 15, 2023

SELL
$4.0 - $7.02 $78,972 - $138,595
-19,743 Reduced 2.18%
884,633 $3.64 Million
Q4 2022

Feb 13, 2023

BUY
$5.65 - $7.86 $181,681 - $252,746
32,156 Added 3.69%
904,376 $5.3 Million
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $72,848 - $125,872
15,734 Added 1.84%
872,220 $5.9 Million
Q2 2022

Aug 12, 2022

BUY
$2.84 - $5.0 $375,536 - $661,155
132,231 Added 18.26%
856,486 $3.96 Million
Q1 2022

May 13, 2022

SELL
$3.74 - $6.63 $88,342 - $156,607
-23,621 Reduced 3.16%
724,255 $2.89 Million
Q4 2021

Feb 08, 2022

BUY
$5.48 - $9.86 $278,729 - $501,509
50,863 Added 7.3%
747,876 $4.65 Million
Q3 2021

Nov 15, 2021

BUY
$8.56 - $14.47 $122,630 - $207,297
14,326 Added 2.1%
697,013 $6.57 Million
Q2 2021

Aug 13, 2021

BUY
$13.28 - $18.07 $1.19 Million - $1.62 Million
89,467 Added 15.08%
682,687 $9.27 Million
Q1 2021

May 12, 2021

SELL
$15.31 - $26.52 $586,648 - $1.02 Million
-38,318 Reduced 6.07%
593,220 $9.6 Million
Q4 2020

Feb 11, 2021

SELL
$16.84 - $27.59 $67,090 - $109,918
-3,984 Reduced 0.63%
631,538 $16.8 Million
Q3 2020

Nov 16, 2020

BUY
$16.2 - $25.7 $6.64 Million - $10.5 Million
409,667 Added 181.38%
635,522 $11.8 Million
Q2 2020

Aug 14, 2020

SELL
$5.24 - $23.4 $930,010 - $4.15 Million
-177,483 Reduced 44.0%
225,855 $5.29 Million
Q1 2020

May 14, 2020

BUY
$4.41 - $9.28 $64,924 - $136,620
14,722 Added 3.79%
403,338 $2.35 Million
Q4 2019

Feb 14, 2020

BUY
$1.45 - $6.73 $336 - $1,561
232 Added 0.06%
388,616 $2.23 Million
Q3 2019

Nov 13, 2019

BUY
$1.54 - $4.2 $283,652 - $773,598
184,190 Added 90.2%
388,384 $614,000
Q2 2019

Aug 13, 2019

BUY
$3.84 - $6.4 $92,643 - $154,406
24,126 Added 13.4%
204,194 $827,000
Q1 2019

May 13, 2019

BUY
$3.51 - $7.3 $143,748 - $298,964
40,954 Added 29.44%
180,068 $947,000
Q4 2018

Feb 12, 2019

SELL
$3.45 - $9.72 $23,860 - $67,223
-6,916 Reduced 4.74%
139,114 $567,000
Q3 2018

Nov 14, 2018

BUY
$10.0 - $19.02 $188,680 - $358,869
18,868 Added 14.84%
146,030 $1.46 Million
Q2 2018

Aug 14, 2018

BUY
$14.2 - $22.68 $220,000 - $351,381
15,493 Added 13.87%
127,162 $2.27 Million
Q1 2018

May 09, 2018

BUY
$13.56 - $18.48 $796,555 - $1.09 Million
58,743 Added 110.99%
111,669 $1.76 Million
Q4 2017

Feb 14, 2018

BUY
$14.95 - $19.9 $219,839 - $292,629
14,705 Added 38.47%
52,926 $870,000
Q3 2017

Nov 13, 2017

BUY
$14.8 - $18.06 $565,670 - $690,271
38,221
38,221 $661,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $195M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.